Cases of anaphylaxis after the Comirnaty© vaccine and promotion of allergy epidemic are unfavourable for the National Vaccination Programme – recommendations of the epidemiology experts-team and of the national consultant in allerglogy are unrealistic

Abstract

No cases of anaphylaxis were registered In the clinical trials of the Pfizer-BioNTech and Moderna mRNA vaccines In December mass vaccination programs have been implemented in the United Kingdom and in the United States In the U K two anaphylactic episodes were registered after the first dose of the mRNA Pfizer vaccine which were two women with known food and drug allergies At least a dozen episodes have been reported in the USA It was also speculated that the incidence of anaphylaxis due to usage of the Pfizer vaccine, might be 10-times higher, as the incidence with all other vaccines Anaphylactic episodes related to mRNA Moderna vaccine seems to be rarer In response to the first two episodes, related to the Pfizer vaccine, the MHRA excluded any person with an history of anaphylaxis after food, drug, or vaccine In the USA, the CDC excluded any person who has a history of a severe or immediate allergic reaction associated with any of the vaccine components, such as polyethylene glycol (PEG) and other glycols We believe the reasoning behind that this is too vague and these precautions are too extreme Thy only security measure that should be applied is post vaccinal surveillance on global, national and individual level Appropriate reference points are accessible These are as follow: revised nomenclature for allergy for global use, as well, definitions and management principles of adverse drug reactions In Poland vaccination program started at the end of December On December 26, recommendations of our Epidemiology Experts-team appeared Unfortunately these are a just compilation of MHRA and CDC precautions Recommendations of the National Consultant in Allergology appeared on December 28 Instead exclusion of every person with an history of anaphylaxis after food, drug, or vaccine, a special caution is recommended after every episode It is required that an allergist detects sensi-tisations to all ingredients of the Comirnaty© vaccine In fact this is unrealistic In Poland these substances are not accessible for the routine diagnostic Unfortunately the global unified terminology for allergy and adverse drug reactions is rarely respected by academicians, and by allergists The real prevalence of clinically relevant phenomenon of individual hypersensitivity, allergic and nonallergic alike, remains unclear or misinterpreted This disturbs the doctor’ s logical reasoning and increase the patient`s fears